Analysts' Ratings Review: Geron Corporation (GERN)

Marco Green
November 14, 2017

What Historical Figures Say About Geron Corporation (NASDAQ: GERN)? The consensus mean EPS for the current quarter is at $-0.04 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01.

Shares of Geron Corporation (NASDAQ:GERN) traded down -5.34% in the last session while performance was up 1.95% in the last five days. In the most recent quarter, institutional ownership increased by a net of 2.06 million shares, or 3.29%.This is a bullish sign and indicates that institutions are feeling more optimistic about the outlook for GERN overall.48 holders increased their positions, 44 decreased their positions, and 35 holders held their positions. Now the price is sitting at -8.96% lower than its 50 days moving average.

Bears reigned on a brightened-volume day for Geron Corporation (NASDAQ:GERN) which lost $-0.08 between open and close. BidaskClub downgraded shares of Geron Corporation from a "hold" rating to a "sell" rating in a research report on Saturday, August 5th. Geron Corporation had a negative net margin of 2,992.67% and a negative return on equity of 25.14%.

2,889K shares changed hands on Monday. During the same period in the prior year, the business posted $0.17 earnings per share.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Geron Corporation (NASDAQ:GERN) high price target of $5 and with a conservative view have low price target of $2.5. Zacks Investment Research lowered Geron Corporation from a buy rating to a hold rating in a research note on Tuesday, July 11th. The average investment rating for GERN on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 4.00 or a Moderate Buy. Their revenue meanwhile grew by 52.94% from the last quarter, totaling $260000.

COPYRIGHT VIOLATION NOTICE: "Favorable Media Coverage Somewhat Unlikely to Affect Geron Corporation (GERN) Stock Price" was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and global copyright and trademark law. The legal version of this article can be accessed at BlackRock Investment Management LLC boosted its stake in Geron 4.0% in the second quarter. Russell Investments Group Ltd. acquired a new position in shares of Geron Corporation in the 2nd quarter worth approximately $114,000. Parametric Portfolio Associates LLC now owns 47,976 shares of the biopharmaceutical company's stock worth $133,000 after acquiring an additional 17,877 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Geron Corporation by 59.4% in the second quarter. Janney Montgomery Scott LLC now owns 132,200 shares of the biopharmaceutical company's stock valued at $354,000 after buying an additional 65,100 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Geron 0.5% in the second quarter.

Geron Corporation (Geron), launched on November 28, 1990, is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. The Company is engaged in the development of therapeutic products for oncology.

Other reports by Click Lancashire

Discuss This Article